Who are S-1 single's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Unitrim, Pemetrexed + oral folinic acid rescue, Intrathecal injection of pemetrexed, Pemetrexed therapy, Pemetrexed+carboplatin/Cisplatin, PemCarbo.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-1-single.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

S-1 single — Competitive Intelligence Brief

S-1 single (S-1 single) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral fluoropyrimidine combination. Area: Oncology.

phase 3 Oral fluoropyrimidine combination Thymidylate synthase, dihydrofolate reductase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

S-1 single (S-1 single) — Sun Yat-sen University. S-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and other folate metabolism enzymes to disrupt DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
S-1 single TARGET	S-1 single	Sun Yat-sen University	phase 3	Oral fluoropyrimidine combination	Thymidylate synthase, dihydrofolate reductase
Unitrim	BRODIMOPRIM		marketed	brodimoprim	Bifunctional dihydrofolate reductase-thymidylate synthase, Dihydrofolate reductase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Intrathecal injection of pemetrexed	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed therapy	Pemetrexed therapy	The First Affiliated Hospital with Nanjing Medical University	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed+carboplatin/Cisplatin	Pemetrexed+carboplatin/Cisplatin	Suzhou Puhe Pharmaceutical Technology Co., LTD	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
PemCarbo	PemCarbo	Asan Medical Center	phase 3	Chemotherapy combination (antifolate + platinum agent)	Thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral fluoropyrimidine combination class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S-1 single — Competitive Intelligence Brief. https://druglandscape.com/ci/s-1-single. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab